IHS Chemical Week

Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals

Piramal and Lilly Enter Major Drug Development Deal

1:00 PM MDT | July 25, 2007 | Deepti Ramesh

Eli Lilly and Nicholas Piramal India Ltd. (NPIL; Mumbai), one of India’s biggest manufacturers of pharmaceuticals, have signed a major agreement to develop and market some of Lilly’s preclinical drug candidates covering a wide range of therapeutic areas. The agreement sets a new pattern in alliances for drug discovery and development, experts say. NPIL will be responsible for design and execution of the program, and the resulting developmental drugs will be registered with U.S. FDA as Investigational New Drug Applications (IND). Lilly and NPIL will...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa